| Identification | Back Directory | [Name]
2-(3-oxo-1H-isoindol-2-yl)-2-phenyl-N-(1,3-thiazol-2-yl)acetamide | [CAS]
892772-75-7 | [Synonyms]
2-(1-Oxoisoindolin-2-yl)-2-phenyl-N-(thiazol-2-yl)acetamide
2-(3-oxo-1H-isoindol-2-yl)-2-phenyl-N-(1,3-thiazol-2-yl)acetamide
2H-Isoindole-2-acetamide, 1,3-dihydro-1-oxo-α-phenyl-N-2-thiazolyl- | [Molecular Formula]
C19H15N3O2S | [MOL File]
892772-75-7.mol | [Molecular Weight]
349.41 |
| Chemical Properties | Back Directory | [density ]
1.424±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, away from moisture and light | [form ]
Solid | [pka]
7.57±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
EAI001 was the first non-ATP competitive EGFRL858R/T790M/C797S inhibitor. | [Uses]
EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer[1][2]. | [References]
[1] Maity S, et, al. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance. Pharmacol Rep. 2020 Aug;72(4):799-813. DOI:10.1007/s43440-020-00131-0
[2] Tinivella A, et, al. Investigating the selectivity of allosteric inhibitors for mutant t790m egfr over wild type using molecular dynamics and binding free energy calculations. 2018 Dec 4;3(12):16556-62. |
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|